| Drugs by Condition |  |
Hypertriglyceridemia Medications
Drugs (by generic name) associated with Hypertriglyceridemia
The following drugs and medications are in some way related to, or used in the treatment of Hypertriglyceridemia. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.
Drug Name  ( View by: Brand | Generic )
|
Reviews | Ratings |
||
|---|---|---|---|---|
omega-3 polyunsaturated fatty acids systemic (More...) class: nutraceutical products | 3 review(s) |  | 9.8 | |
| fenofibrate systemic (Pro, More...)class: fibric acid derivatives | 5 review(s) | | 4.6 | |
| fenofibric acid systemic (Pro, More...)class: fibric acid derivatives | 3 review(s) | | 4.3 | |
Hypertriglyceridemia Medications in the Pipeline
MK-0524A (niacin ER and laropiprant)
- June 20, 2008 - Merck Provides Update on U.S. Regulatory Status of MK-0524A (ER niacin/laropiprant) and MK-0524B (ER niacin/laropiprant/simvastatin)
- April 29, 2008 - Merck Receives Not Approvable Letter from FDA for MK-0524A (ER niacin/laropiprant)
- August 29, 2007 - Merck Announces FDA Acceptance of NDA for Cordaptive (ER niacin/laropiprant), Formerly Known as MK-0524A, an Investigational Lipid-Modifier
Certriad (rosuvastatin calcium and fenofibric acid)
Latest Hypertriglyceridemia Blog Post
Essentialis Meets Primary Endpoint in Phase 2b Trial of DCCR for Treatment of Hypertriglyceridemia and is Granted Extensive Patent Coverage in the US
CARLSBAD, Calif., May 17 /PRNewswire/ -- Essentialis Inc, a clinical stage pharmaceutical company, announced today that it met its primary endpoint of statistically significant triglyceride reduction in a 90-patient Phase 2b trial of DCCR in dyslipidemic...
View all Hypertriglyceridemia blog posts.
